LUNG CANCER

Benjamin P. Levy, MD, discusses how Myriad's myPlan addresses the risk of recurrence in lung cancer.

Results of a recent randomized trial showed first-line therapy with nivolumab failed to improve progression-free survival (PFS) in PD-L1–positive non-small cell lung cancer (NSCLC) compared with standard chemotherapy.

Almost 40% of patients with resected early-stage non–small cell lung cancer (NSCLC) had evidence of tumor regression following neoadjuvant treatment with nivolumab (Opdivo) in a preliminary clinical trial.

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

Progression-free survival (PFS) was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced <em>ALK</em>-positive non&ndash;small cell lung cancer (NSCLC) who progressed after first-line crizotinib.

Atezolizumab (Tecentriq) reduced the risk of death by 27% compared with docetaxel in patients with advanced non&ndash;small cell lung cancer (NSCLC) following the failure of platinum-based chemotherapy.

Single-agent pembrolizumab (Keytruda) reduced the risk of death by 40% and improved progression-free survival (PFS) by 4.3 months compared with doublet chemotherapy for untreated patients with advanced non&ndash;small cell lung cancer (NSCLC) with PD-L1 expression on &ge;50% of cells, according to findings from the phase III KEYNOTE-024 trial.

Benjamin P.&nbsp;Levy, MD, medical director of thoracic medical oncology for Mount Sinai Health Systems and the associate medical director of the cancer clinical trials office for Mount Sinai Hospital, New York,&nbsp;discusses the tools currently available for predicting mortality risk in patients with early stage lung cancer.

Recent randomized clinical trials that have combined immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy for the treatment of patients with&nbsp;lung cancer have shown promising results for these combinations.&nbsp;

Roy S. Herbst, MD, PhD, discusses the immunotherapy combinations under investigation in NSCLC&nbsp;during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

The c-MET inhibitor capmatinib (INC280) demonstrated early signals of efficacy with an overall response rate (ORR) of 20% when administered to patients with advanced c-MET&ndash;dysregulated non&ndash;small cell lung cancer (NSCLC).